These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11266783)

  • 1. Intracellular signaling consequences of anti-IL-2Ralpha blockade by daclizumab.
    Tkaczuk J; Milford E; Yu C; Baksh S; Carpenter C; Burakoff S; McKay D
    Transplant Proc; 2001; 33(1-2):212-3. PubMed ID: 11266783
    [No Abstract]   [Full Text] [Related]  

  • 2. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events.
    Goebel J; Stevens E; Forrest K; Roszman TL
    Transpl Immunol; 2000 Nov; 8(3):153-9. PubMed ID: 11147695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-15R alpha-chain expression during anti-CD25 treatment of cardiac allograft recipients.
    Baan CC; Balk AH; van der Plas AJ; van Gelder T; Vantrimpont PJ; Maat LP; Weimar W
    Transplant Proc; 2002 Dec; 34(8):3243-5. PubMed ID: 12493434
    [No Abstract]   [Full Text] [Related]  

  • 4. Daclizumab: a potential asthma therapy?
    Antoniu SA
    Recent Pat Inflamm Allergy Drug Discov; 2010 Nov; 4(3):214-21. PubMed ID: 20804450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Window of opportunity for daclizumab.
    Schluns KS
    Nat Med; 2011 May; 17(5):545-7. PubMed ID: 21546970
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation.
    Koch M; Niemeyer G; Patel I; Light S; Nashan B
    Transplantation; 2002 May; 73(10):1640-6. PubMed ID: 12042653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-7 and IL-15 bypass the immunosuppressive action of anti-CD25 monoclonal antibodies.
    Baan CC; Boelaars-van Haperen MJ; van Riemsdijk IC; van der Plas AJ; Weimar W
    Transplant Proc; 2001 May; 33(3):2244-6. PubMed ID: 11377516
    [No Abstract]   [Full Text] [Related]  

  • 8. Daclizumab rapidly saturates interleukin-2 receptor-alpha (CD25) on lymph node lymphocytes in children.
    Savo AM; Book BK; Henson S; Hakimi J; Pescovitz MD
    Transplant Proc; 1999; 31(1-2):1182-3. PubMed ID: 10083528
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling.
    Tkaczuk J; Yu CL; Baksh S; Milford EL; Carpenter CB; Burakoff SJ; McKay DB
    Am J Transplant; 2002 Jan; 2(1):31-40. PubMed ID: 12095053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockade.
    ter Meulen CG; Baan CC; Hené RJ; Hilbrands LB; Hoitsma AJ
    Transplantation; 2001 Nov; 72(10):1709-10. PubMed ID: 11726840
    [No Abstract]   [Full Text] [Related]  

  • 11. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.
    Martin JF; Perry JS; Jakhete NR; Wang X; Bielekova B
    J Immunol; 2010 Jul; 185(2):1311-20. PubMed ID: 20543101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production.
    McDyer JF; Li Z; John S; Yu X; Wu CY; Ragheb JA
    J Immunol; 2002 Sep; 169(5):2736-46. PubMed ID: 12193748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab.
    Binder M; Vögtle FN; Michelfelder S; Müller F; Illerhaus G; Sundararajan S; Mertelsmann R; Trepel M
    Cancer Res; 2007 Apr; 67(8):3518-23. PubMed ID: 17440057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
    Van Gelder T; Warlé M; Ter Meulen RG
    Drugs; 2004; 64(16):1737-41. PubMed ID: 15301558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy.
    Wuest SC; Edwan JH; Martin JF; Han S; Perry JS; Cartagena CM; Matsuura E; Maric D; Waldmann TA; Bielekova B
    Nat Med; 2011 May; 17(5):604-9. PubMed ID: 21532597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of interleukin-2 on immune response regulation.
    Waters RS; Perry JSA; Han S; Bielekova B; Gedeon T
    Math Med Biol; 2018 Mar; 35(1):79-119. PubMed ID: 28339682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis.
    Krueger JG; Walters IB; Miyazawa M; Gilleaudeau P; Hakimi J; Light S; Sherr A; Gottlieb AB
    J Am Acad Dermatol; 2000 Sep; 43(3):448-58. PubMed ID: 10954656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of immunosuppression by the therapeutic antibody daclizumab.
    Yang H; Wang J; Du J; Zhong C; Zhang D; Guo H; Guo Y; Ding J
    Cell Res; 2010 Dec; 20(12):1361-71. PubMed ID: 20820193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interleukin-2 inhibitors and their role in low-toxicity regimens.
    Nashan B
    Transplant Proc; 1999 Dec; 31(8A):23S-26S. PubMed ID: 10616557
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.